Orakl Oncology raises $34m to improve cancer drug development

French biotechnology company Orakl Oncology has raised approximately $34m in Series A funding to expand its technology for testing potential cancer treatments. The business combines patient-derived tumour models with artificial intelligence and biological data to help pharmaceutical companies assess new medicines before clinical trials. HPC could identify pharmaceutical manufacturers, laboratory equipment suppliers, clinical research organisations, medical technology companies and healthcare investors interested in the growing biotechnology market.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.